Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$9.83
+1.5%		$9.66
$6.00
▼
$11.22
$2.47B0.553.31 million shs2.33 million shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$77.46
+0.5%		$80.25
$35.22
▼
$88.31
$9.59B0.381.89 million shs1.26 million shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$61.09
-1.3%		$56.91
$29.87
▼
$65.00
$9.21B1.23948,692 shs1.22 million shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$107.36
+0.7%		$98.16
$14.51
▼
$110.18
$9.38B3.03853,214 shs909,543 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
+1.26%-2.62%+3.64%+14.29%+13.08%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
+0.33%+1.61%-4.52%+1.05%+101.07%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-1.20%+2.74%+13.19%+23.47%+91.61%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
+0.15%+1.96%+4.43%+44.81%+513.64%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$9.83
+1.5%		$9.66
$6.00
▼
$11.22
$2.47B0.553.31 million shs2.33 million shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$77.46
+0.5%		$80.25
$35.22
▼
$88.31
$9.59B0.381.89 million shs1.26 million shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$61.09
-1.3%		$56.91
$29.87
▼
$65.00
$9.21B1.23948,692 shs1.22 million shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$107.36
+0.7%		$98.16
$14.51
▼
$110.18
$9.38B3.03853,214 shs909,543 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
+1.26%-2.62%+3.64%+14.29%+13.08%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
+0.33%+1.61%-4.52%+1.05%+101.07%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-1.20%+2.74%+13.19%+23.47%+91.61%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
+0.15%+1.96%+4.43%+44.81%+513.64%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
2.67
Moderate Buy$20.60109.56% Upside
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.86
Moderate Buy$102.2031.94% Upside
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
2.50
Moderate Buy$86.0040.78% Upside
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
2.87
Moderate Buy$111.694.04% Upside

Current Analyst Ratings Breakdown

Latest BCRX, CYTK, SYRE, and PCVX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/13/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$95.00 ➝ $110.00
8/13/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$97.00 ➝ $103.00
8/12/2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/11/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$112.00 ➝ $132.00
8/10/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$106.00 ➝ $112.00
8/7/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$117.00 ➝ $112.00
8/7/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/7/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Outperform$105.00 ➝ $110.00
8/7/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$102.00 ➝ $112.00
8/6/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$14.00 ➝ $13.00
(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$874.84M2.87$1.26 per share7.82($1.78) per share-5.52
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$88.04M109.48N/AN/A($1.39) per share-55.73
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$18.53 per shareN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$890K10,608.13N/AN/A$10.86 per share9.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$263.86M-$1.50N/A13.65N/A-40.90%-86.89%66.37%11/2/2026 (Estimated)
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$784.96M-$7.22N/AN/AN/A-1,321.12%N/A-51.01%11/4/2026 (Estimated)
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$766.63M-$7.63N/AN/AN/AN/A-37.56%-33.62%11/3/2026 (Estimated)
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$155.20M-$1.95N/AN/AN/AN/A-30.74%-22.23%11/3/2026 (Estimated)

Latest BCRX, CYTK, SYRE, and PCVX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.63-$1.50+$0.13-$1.50$17.59 million$28.62 million
8/5/2026Q2 2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$0.1542$0.30+$0.1458$0.30$183.28 million$218.25 million
8/5/2026Q2 2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$2.06-$1.97+$0.09-$1.97$12.50 millionN/A
8/4/2026Q2 2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$0.7589-$0.36+$0.3989-$0.36N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/AN/AN/AN/AN/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/A
2.32
2.29
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
6.66
6.66
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
5.72
5.72
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/A
18.53
18.53

Institutional Ownership

CompanyInstitutional Ownership
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
85.88%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
80.39%

Insider Ownership

CompanyInsider Ownership
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
3.80%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.60%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.30%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
15.69%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
530255.54 million245.83 millionOptionable
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
250124.43 million121.20 millionOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160148.80 million143.89 millionOptionable
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
7387.94 million74.14 millionOptionable

Recent News About These Companies

Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
August 25 at 4:01 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/25/3350866/0/en/spyre-therapeutics-announces-topline-results-from-the-rheumatoid-arthritis-sub-study-of-the-skyway-phase-2-trial-of-spy072.html
Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?
August 24 at 12:31 PM  |  zacks.comhttps://www.zacks.com/stock/news/2979109/can-spyre-s-spy772-hs-study-broaden-its-growth-story-beyond-core-ibd?cid=cs-stocknewsapi-ft-analyst_blog_plus|zer_report_insights-2979109
Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?
August 24 at 12:31 PM  |  zacks.comhttps://www.zacks.com/stock/news/2979112/is-syre-a-buy-now-as-clinical-catalysts-clash-with-valuation-risk?cid=cs-stocknewsapi-ft-analyst_blog_plus|zer_report_insights-2979112
SYRE Rallies 44.9% in 3 Months. Can Clinical Catalysts Sustain It?
August 24 at 11:11 AM  |  zacks.comhttps://www.zacks.com/stock/news/2979019/syre-rallies-44-9-in-3-months-can-clinical-catalysts-sustain-it?cid=cs-stocknewsapi-ft-analyst_blog_plus|zer_report_insights-2979019
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/spyre-therapeutics-inc-nasdaqsyre-receives-consensus-recommendation-of-moderate-buy-from-brokerages-2026-08-21/
This stock’s already up nearly 600% over the past year
August 19, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/this-stock-s-already-up-nearly-600-over-the-past-year/ar-AA2auTn6
Spyre Therapeutics (NASDAQ:SYRE) Hits New 52-Week High - Here's What Happened
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/spyre-therapeutics-nasdaqsyre-hits-new-52-week-high-heres-what-happened-2026-08-18/
LifeSci Capital Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)
August 17, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3876143/lifesci-capital-reaffirms-their-buy-rating-on-spyre-therapeutics-syre/
Handelsbanken Fonder AB Makes New $2.31 Million Investment in Spyre Therapeutics, Inc. $SYRE
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-handelsbanken-fonder-ab-makes-new-231-million-investment-in-spyre-therapeutics-inc-syre-2026-08-17/
Spyre Therapeutics (NASDAQ:SYRE) Downgraded to Sell Rating by Wall Street Zen
August 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30963122
Wall Street Zen Downgrades Spyre Therapeutics (NASDAQ:SYRE) to Sell
August 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/wall-street-zen-downgrades-spyre-therapeutics-nasdaqsyre-to-sell-2026-08-16/
Wedbush Keeps Their Buy Rating on Spyre Therapeutics (SYRE)
August 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SYRE/pressreleases/3804939/wedbush-keeps-their-buy-rating-on-spyre-therapeutics-syre/
Dimensional Fund Advisors LP Sells 29,593 Shares of Spyre Therapeutics, Inc. $SYRE
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-sells-29593-shares-of-spyre-therapeutics-inc-syre-2026-08-14/
Spyre Therapeutics Launches Program, Mid-Stage Trial for Drug Combination to Treat Hidradenitis Suppurativa
August 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/spyre-therapeutics-launches-program-mid-135836608.html
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Expected to Rise, BTIG Research Analyst Says
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/spyre-therapeutics-nasdaqsyre-stock-price-expected-to-rise-btig-research-analyst-says-2026-08-11/
Spyre Therapeutics, Inc. $SYRE Shares Bought by Bank of America Corp DE
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-spyre-therapeutics-inc-syre-shares-bought-by-bank-of-america-corp-de-2026-08-11/
Spyre Therapeutics (NASDAQ:SYRE) Director Sells 18,000 Shares
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/spyre-therapeutics-nasdaqsyre-director-sells-18000-shares-2026-08-10/
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
August 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/spyre-therapeutics-announces-launch-of-spy772-program-and-initiation-of-phase-2-skylight-trial-in-hidradenitis-suppurativa-1036435462
California State Teachers Retirement System Purchases 11,204 Shares of Spyre Therapeutics, Inc. $SYRE
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-purchases-11204-shares-of-spyre-therapeutics-inc-syre-2026-08-10/
Can Spyre Therapeutics (SYRE) Justify Its Premium After Positive Phase 2 Data?
August 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/spyre-therapeutics-syre-justify-premium-032005901.html
Spyre Therapeutics (NASDAQ:SYRE) Stock Rating Upgraded by Wall Street Zen
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/spyre-therapeutics-nasdaqsyre-stock-rating-upgraded-by-wall-street-zen-2026-08-08/

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioCryst Pharmaceuticals stock logo

BioCryst Pharmaceuticals NASDAQ:BCRX

$9.83 +0.15 (+1.55%)
Closing price 04:00 PM Eastern
Extended Trading
$9.85 +0.02 (+0.15%)
As of 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Cytokinetics stock logo

Cytokinetics NASDAQ:CYTK

$77.46 +0.37 (+0.48%)
Closing price 04:00 PM Eastern
Extended Trading
$77.56 +0.10 (+0.12%)
As of 05:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$61.09 -0.78 (-1.26%)
Closing price 04:00 PM Eastern
Extended Trading
$61.12 +0.02 (+0.04%)
As of 04:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Spyre Therapeutics stock logo

Spyre Therapeutics NASDAQ:SYRE

$107.36 +0.71 (+0.67%)
Closing price 04:00 PM Eastern
Extended Trading
$94.32 -13.04 (-12.15%)
As of 05:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas